Realbio Completes $15 Million Series A+ for Genome and Microbiome Screening

Realbio Technology (RBT), a Shanghai genomic screening company, raised $15 million in a Series A+ funding. The company has a dual focus on colorectal and microbiome screening. RBT operates in three areas: REALGENE provides scientific research services; REALMED offers early detection of disease based on genomic sequencing including microbiome research, and REALAGR specializes in animal genomics. Founded in 2014, RBT has set up branches in Hangzhou, Qindao, Guiyang and other places. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.